Skip to content

Berberine treatment for acute gastrointestinal injury with sepsis: a single-center, randomized, double-blind, controlled trial

Berberine treatment for acute gastrointestinal injury with sepsis: a single-center, randomized, double-blind, controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000034974
Enrollment
Unknown
Registered
2020-07-26
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis, acute gastrointestinal injury

Interventions

trial group:Berberine + compound B vitamin
control group:compound B vitamin

Sponsors

Shenzhen Second People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Hospitalized patients aged >= 18 years and less than 80 years. 2. Meet the diagnostic criteria of septic shock in the 2016 guidelines for the treatment of severe infection and septic shock, that is to say, sepsis is diagnosed with persistent hypotension, and even after adequate volume resuscitation treatment, hypertension drugs are required to maintain MAP >= 65mmHg and blood lactate level > 2mmol/L (18mg/dl). 3. AGI diagnostic and quantitative scoring criteria for acute gastrointestinal injury were met.

Exclusion criteria

Exclusion criteria: 1. Acute central nervous system diseases (stroke, traumatic brain injury); 2. Severe abdominal trauma; 3. Acute myocardial infarction, severe arrhythmia, heart failure and shock (IABP), cardiopulmonary resuscitation; 4. Primary neuromuscular lesions; 5. Drug, alcohol, opioid or amphetamine dependence, mental disorders; 6. Maternal; 7. Advanced malignant tumor or malignant fluid or terminal chronic disease; 8. Death is expected within ICU 24h; 9. Previous berberine allergy.

Design outcomes

Primary

MeasureTime frame
AGI graded mitigation;

Secondary

MeasureTime frame
28-day mortality rate;60-Day mortality rate;inflammation;Blood coagulation;

Countries

China

Contacts

Public ContactMing Wu

Shenzhen Second People's Hospital

gyzhiye@qq.com+86 15814468590

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026